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Scientific principles demand that before newly developed alternative methods for safety testing
are fully embraced by the industrial or regulatory community, they reliably and reproducibly
predict the designated toxic end point. The process used to determine reliability and
reproducibility is termed validation, and it generally culminates with a highly controlled, blinded
study using multiple chemicals and laboratories. It is imperative that the validation study is
designed to confirm the previously established reproducibility and predictive power of the assay.
Much has been learned recently about the practical aspects of validation through investigation of
alternative methods for acute toxicity testing, i.e., those methods that assess acute systemic
toxicity, skin irritation, and eye irritation. Although considerable progress has been made-many
alternative tests are now commonly used in various industrial settings-there have been few
tests that have successfully passed a complete validation. Some of the barriers to successful
validation have been a) lack of high-quality, reproducible animal data; b) insufficient knowledge of
the fundamental biologic processes involved in acute toxicity; and c) the development of truly
robust in vitro assays that can accurately respond to materials with a wide range of chemical and
physical characteristics. It is recommended that to progress in the areas of eye and skin irritation
we need to expand our knowledge of toxic markers in humans and the biochemical basis of
irritation; progress in the area of acute systemic toxicity will require the development of in vitro
models to determine gastrointestinal uptake, blood-brain barrier passage, and biotransformation.
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Introduction
In applying scientific principles to the throughout the history of science by less
problem of determining acceptability of structured but scientifically rigorous
new, alternative methods for safety testing, approaches. This validation has been
there is a need for a standard validation accomplished during the development of
process. This validation process is described individual methodologies, publication of
and referenced in this document. Scientific results in peer-reviewed journals, repetition
methodologies have been validated ofstudies by independent laboratories, and
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acceptance by widespread use of the
method. This less structured, but rigorous
and scientifically acceptable approach will
and should continue. However, it has
become clear that more rapid progress will
result ifa more structured, formal approach
to validation is adopted. This would
include having a set of explicit criteria to
use in the evaluation of any new method.
As methods are reviewed for regulatory
use, supportive data for compliance with
how each method meets well-established
criteria will provide a more rapid and
effective review.
Use ofAlternative Methods
in AcuteToxicityTesting
Considerable research has been directed
toward the development and validation of
alternative methods for acute toxicity test-
ing. Acute toxicity tests assess acute oral
toxicity, skin irritation, and eye irritation.
These tests are important for assessing
chemical hazards due to a single short-
term exposure to a chemical. Historically,
these assessments have been conducted in
whole animals with the assumption that
the results can be extrapolated to humans.
For several important reasons discussed
throughout this document, it would be
useful to replace these animal-based tests
with nonanimal alternative methods. A
scheme for the inclusion of alternative
methods in a typical safety assessment
process is shown in Figure 1. The first step
in such processes usually includes a review
of the historical data available on the
chemical and an assessment of its physi-
cal-chemical properties. In many cases,
quantitative structure-activity relationship
(QSAR) models may be useful for such
assessments. In some cases it is possible to
characterize the chemical hazard based on
these data alone. If more data are needed,
the next step in the process is to conduct
testing in some type of in vitro biological
system. The new data are integrated with
any other available information, and again,
it is often possible to characterize the chem-
ical hazard based on the total data package.
Ifit is still not possible to complete the haz-
ard assessment, the next step in the process
is to determine ifhuman data are needed. If
so, it is necessary to consider whether the
available information is sufficient to allow
controlled human exposure. Ifthe data are
sufficient, and ifthe testing is deemed ethi-
cal after independent ethical review, con-
trolled studies may be undertaken. If the
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Figure 1. System for using in vitro assays as part of a tiered testing structure. The diagram illustrates a sequen-
tial process for making the safety assessment of a hypothetical chemical or product. It can be seen that in vitro
methods (as well as traditional animal tests) supply only a portion of the information needed to make the safety
assessment and that this information is integrated with other data so that a weight-of-evidence decision is
finally made.
data are insufficient, testing in appropriate
animal models should be conducted. When
all data are available, the hazard characteri-
zation maybe completed, and human expo-
sure may be allowed depending on the
results ofthe safety assessment.
EvolutionofAlternativeMethods
forAcuteToxicityTesting
Experience in developing and optimizing
in vitro assays for acute toxic end points
has revealed a general pathway through
which most tests pass on their way to
general acceptance by the scientific
community. The pathway is generally
characterized as test development->
optimization/prevalidation--validation--->
acceptance--routine use. These stages can
be defined as follows:
* Test development: Identification of a
toxicological need, developing a model,
defining end point measurements, and
characterizing output
* Optimization/prevalidation: Further
definition ofoperating parameters, stan-
dardization of protocol and standard
operating procedures (SOPs), defining
appropriate controls, obtaining evidence
of transferability and reproducibility,
and defining aprediction model
* Validation: Generally a formalized
method of independently evaluating
the reproducibility and relevance of a
method. Often conducted with coded
materials and in multiple laboratories
* Acceptance: May indicate formal regu-
latory acceptance or acceptance by a set
ofusers after appropriate peer review of
thevalidation data
* Routine use: Standard use of the
defined assay for its specific purpose as
defined within its prediction model.
This progression can occur on many
different levels, for example, within a single
laboratory, within a company, or at a more
general national scale where it may lead to
full regulatory acceptance. However, vali-
dation of the test is necessary at any of
these levels ifother researchers are expected
to accept the usefulness ofthe method and
use it on a routine basis.
Lessons Learned
Much attention has been given to the
development and validation of alternative
methods for acute toxicity testing in recent
years. There are three reasons for this. The
first is to improve the quality of the data
obtained from acute toxicity tests. This is
necessary for toxicologists to better predict
and manage the risks associated with use
of chemicals under defined conditions.
Second, it is hoped that it is possible to
develop methods that are less expensive
and less time consuming. This will cer-
tainly be true for complex long-term stud-
ies such as 2-year bioassays. However, it is
likely that alternative methods for other
types ofstudies, such as some acute toxic-
ity tests, will be more costly and may take
more time. Finally, acute toxicity tests
may be highly stressful to test animals.
This has led to criticism ofthe procedures
on ethical grounds. The development of
nonanimal methods would allow toxicolo-
gists to obtain necessary information with-
out the need for animals in the safety
assessment process.
Numerous methods have been pro-
posed as viable alternatives, and several
large validation studies have been con-
ducted to assess the ultimate utility ofthese
procedures. Although these studies have
not yet led to both the validation and
acceptance ofan alternative method, much
has been learned about the test methods
and also about the procedures that should
be used to assess their acceptability. It is,
therefore, useful to provide a briefoverview
ofthe most important lessons learned from
these efforts.
LesonsLearnedaboutAlternative
MethodDataDevelopment
The development, optimization, pre-
validation, and validation ofan alternative
method for toxicity testing is a long and
complicated process because many of the
mechanisms leading to toxic reactions are
not well defined. This lack ofunderstand-
ing makes it difficult to develop tests that
provide relevant information needed for
making correct decisions in the safety
assessment process.
The basic research needed to develop
mechanistic understanding takes signifi-
cant time. Often this time exceeds the
patience ofgroups seeking the end ofani-
mal testing through political means, and
the extended effort consumes resources of
commercial developers who attempt to
market new test methodologies. Pressures
brought by groups desiring rapid progress
are not unlike those observed in manyother
fields, i.e., at times the pressures facilitate
the ability to focus resources on the prob-
lem. However, such pressures must not lead
to shortcuts that not onlycould damage the
scientific credibility of new methods, but
could even seriously endanger human
health andsafety.
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Lessons LearnedaboutEvaluation
ofDatafromValidation Studies
Validation must be a disciplined process.
Validation studies must be designed so that
they test clearly stated hypotheses and allow
judgment of alternative method perfor-
mance relative to predefined success crite-
ria. This is important whether validation
studies are conducted in a coordinated
fashion or conducted independently in
several unrelated laboratories. Once com-
pleted, the results from a validation study
should be subjected to appropriate peer
review. Developers ofmethods should pre-
sent their work in forums where the results
and conclusions can be openly debated.
Constructive criticism should be given and
accepted in the spirit of improving the
scientific quality of new methods. For
example, the careful review of instances
where a method has failed may lead to
greater understanding ofbasic mechanisms
and improved alternative methods.
Lessons LeanedabouttheTechnical
Aspects ofValidation
Much has been learned about the
development and validation of alternative
methods from a technical point of view.
First, it is important that alternative meth-
ods be fully optimized before they are
assessed in validation studies. Scientists
leading validation studies must assure that
clearly defined protocols and SOPs are
available, that prediction models have been
defined, and that the method is relevant for
its intended use before a validation study is
started. Second, attempts to define criteria
of success have reminded us that the data
obtained from in vivo tests may be less pre-
cise and accurate than desired. Scientists
responsible for developing alternative meth-
ods must find ways to overcome the limita-
tions imposed by the technical inadequacies
ofcurrent tests. The use ofhuman data in
somelimited, ethically acceptable cases may
address this issue to some extent, but will
not solve the overall problem. Finally, there
is a need to increase our understanding of
toxicity mechanisms and then develop new
methods based on this understanding. A
sound mechanistic basis increases confi-
dence in predictions obtained from such
tests and ultimately leads to the generation
ofbetter data for risk assessments.
LessonsLenedabouttheAdequacy
ofDataSourcesforValidation Studies
Human toxicity data can be found in
handbooks, the scientific literature, and in
the databanks of poison information
centers throughout the world; however,
these data are not standardized or normal-
ized. Nonetheless, there is adequate infor-
mation on the acute systemic human
toxicity ofa number ofcompounds to allow
alternative method development, prevalida-
tion, and validation to be conducted with
human data as thestandard.
Current Situation
Validation
The purpose of the validation process is to
provide independent confirmation that an
alternative method provides correct infor-
mation needed for making risk assessments
or for other safety-related decisions.
Accordingly validation must be considered a
confirmatory process, and not a process
involving test method development or test
method optimization. The following para-
graphs provide a brief review of the steps
that should be considered in the validation
process. The discussion is centered around
the flow chart depicted in (Figure 2) and is
based on information contained in reviews
ofvalidation prepared by international bod-
ies such as the Organisation for Economic
Co-operation and Development (OECD)
(1) and from the scientific literature (2-4).
Definitions. Validation has been
defined as the establishment ofthe reliabil-
ity and relevance of an alternative method
for a specific purpose (2-4). Reliability
refers to the demonstration ofreproducibil-
ity ofdata obtained from a test method in
the laboratory and the reproducibility of
the predictions of toxic hazard following
application of a clearly stated prediction
model to the alternative method data (5).
Relevance refers to the establishment ofsci-
entific meaningfulness and usefulness of
results from an alternative method for a
particular purpose (2-4). The establish-
ment of usefulness and meaningfulness is
important because hazard predictions
obtained from scientifically credible alter-
native methods have a higher probability of
being correct.
Validation Process. CONFIRMING THAT
AN ALTERNATIVE METHOD Is DEVELOPED
SUFFICIENTLY TO ALLOW AN ASSESSMENT
OF RELIABILITY AND RELEVANCE. The vali-
dation of an alternative method cannot
be undertaken until it has been suffi-
ciently developed in the pre-validation
stages. Factors that should be considered
during prevalidation have been reviewed
by Curren et al. (6). The most important
are a) there should be strong evidence that
the alternative method is relevant for the
intended purpose; b) there must be clearly
written protocols and SOPs that describe
how to conduct a test method in an appro-
priately equipped laboratory; c) there
should be evidence that data obtained from
the method can be generated reproducibly
across several laboratories; and d) there
must be a prediction model available that
allows correct interpretation ofresults from
the alternative method.
IMPORTANCE OF THE PREDICTION
MODEL. Experience gained during the con-
duct ofrecendy completed validation stud-
ies has highlighted the importance of the
concept of the prediction model. In order
for an alternative method to be useful for
makingsafety assessments, it must be possi-
ble to translate its results into correct pre-
dictions of in vivo toxicity. This is usually
done by applying algorithms to the alterna-
tive method data that converts them into
toxicity predictions. These algorithms are
usually developed from experimental data
generated during the prevalidation stages of
development. Since such algorithms consti-
tute models that allow the prediction of
toxicity, they have been called prediction
models (5). If an alternative method does
not have an adequate prediction model,
there would be no way to use it in the
safety assessment process. It is therefore
essential that validation programs test the
utility of the prediction models. In fact, if
there is no prediction model, there can be
no validation study (7).
MEASURING THE RELIABILITY OF AN
ALTERNATIVE METHOD IN A VALIDATION
STUDY. Factors that must be considered in
the design and conduct ofavalidation study
are listed in Figure 2. The validation study
must be designed based on a knowledge of
the data to be provided by the study. The
participating laboratories must be identified
and recruited. A reference set of test sub-
stances must be assembled, and the quality
of the in vivo data must be assessed. Once
these steps have been completed, each test
substance must be evaluated in the alterna-
tive methods being evaluated in the pro-
gram. Finally, when the data from the
laboratory work are available, the prediction
model must be used to predict the in vivo
toxicityofeach test substance. Ifthe toxicity
predictions are similar to the actual toxicity
ofthe test substances, and ifthe same results
were obtained in each of the participating
laboratories, it would provide evidence that
the method is reliable. If, however, the toxi-
city is not predicted correctly or if the
results are not similar across the participat-
ing laboratories, it would not be possible to
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Figure 2. The validation process. The flow chart depicts the series of steps that may be used as a guide to design
and conduct a validation program. The steps proceeding down the left side of the chart represent the validation
process. The steps proceeding up the right side ofthe chart depictthe steps associated with improving the perfor-
mance ofthe alternative method and defining another prediction model priorto inclusion ofthe method in a subse-
quent validation study. Any new method, whether it is based on a fundamental understanding oftoxic mechanisms
or based on empirical correlations may be assessed forvalidity using this approach. From Bruner et al. (5).
consider the method reliable. Ifthe alterna-
tive method is not reliable, the validation
process should end so that further method
development may be undertaken (Figure 2).
Ifthe optimization process is successful, the
method may be evaluated in a subsequent
study. Alternatively, the alternative method
may be abandoned if additional work is
unlikely to be fruitful. If the alternative
method is reliable, the next step in the
validation process is to assess its relevance
(Figure 2).
ASSESSING THE RELEVANCE OF AN
ALTERNATIVE METHOD. As noted above,
an alternative method may be considered
relevant when the predictions of toxicity
obtained are meaningful and useful for a
specific purpose. The establishment ofrele-
vance is a judgmental process that requires
the evaluation ofall the available support-
ing data and scientific evidence supporting
the use of an alternative method. It may
also involve evaluation ofkey performance
benchmarks that can provide a useful con-
text for interpreting the results obtained
from avalidation study.
Establishingperformance benchmarks
based on performance characteristics ofthe
alternative method and the tests it will
replace. One ofthe approaches that can be
used for assessing relevance is to estimate
the theoretical best performance that may
be expected from an alternative method.
Ideally, there should be a good correlation
between the in vivoand alternative method
data, and a narrow 95% prediction interval
associated with each prediction oftoxicity.
However, technical limitations in the in
vivo tests and alternative methods most
commonly prevent this ideal from being
reached. Computer simulations based on
an understanding of both the alternative
method and the in vivo test to be replaced
may be used to provide guidance on the
performance levels that may be expected
in a validation study. Practical examples
demonstrating how this may be done have
been described elsewhere (5).
Another important benchmark to
consider is a comparison between theperfor-
mance of the alternative method with the
performance of the method that will be
replaced. Thepredictive capacityofthealter-
native method should be equivalent or
greater than the method that will be
replaced. Again, computer simulations may
provide data-based guidance useful forjudg-
ing the acceptability ofpredictions from an
alternative method. A practical example
showing how computer simulations may be
conductedhas been presentedelsewhere (5).
Otherfactors to consider in assessment of
relevance. In addition to the performance
benchmarks given above, it is important to
consider other factors supporting the rele-
vance ofan alternative method. One ofthe
most important is a consideration ofthe
mechanistic basis of an alternative method.
This is important because a strong mecha-
nistic basis often supports the rationale for
an alternative method, and helps increase
confidence that the predictions from a new
test will be correct. It is also important to
define the known limitations in the use of
an alternative method. For example, a new
procedure may be valid for only a small
number of substances relative to the uni-
verse ofmaterials that must be tested. Ifthe
method is limited in its application, it may
not be relevant for general use in the safety
assessment process. The technical limita-
tions ofan alternative method must also be
known. An assay that can handle all types of
test substances may ultimately be more rele-
vant for general use than one restricted to
only one type (e.g., water-soluble test mate-
rials). Finally, the scientific literature con-
cerning the performance of the alternative
shouldalso be taken into account.
Once all of this information has been
assembled and evaluated, the overall rele-
vance of the method for its defined pur-
pose must be assessed. If the conclusion is
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that the alternative method is not relevant,
the test cannot be considered valid and it is
necessary to consider whether there is value
in optimizing the assay, developing a new
prediction model, and assessing it in a sub-
sequent validation study (Figure 2) (1).
Conversely, if the data support its rele-
vance, then it would suggest the alternative
method can be used in the safety assess-
ment process and should be considered for
official acceptance by regulatory authorities
(Figure 2) (1).
OcularIrritation
Status. In recent years many methods have
been proposed as alternatives to the animal
ocular irritation test. To date, none of
these have been shown to be complete
replacements for the existing animal test.
The failure to find a complete replacement
is likely due to several reasons:
* The eye is a complex organ made up of
multiple tissues, each ofwhich responds
somewhat differently to injury. Current
animal tests for ocular irritation use a
complex scoring system involving a com-
bination of data from three important
ocular tissues.
* In vitro tests have generally been
designed to model only one, or just a
few ocular tissues, not the whole eye.
This can be very helpful in obtaining
mechanistic information, but it is a dis-
advantage if the in vitro tests are
required to accurately reproduce Draize
scores that reflect total eye injury.
* Validation of in vitro ocular irritation
assays will be difficult because the animal
test itself is not very reproducible and
because compounds listed in the histori-
cal databases maynolongerbeavailable.
* Many in vitro tests, by their physical
nature, may be unable to cope with
materials that are solids, water insoluble,
have extremes of pH, or cause damage
by direct physical means (e.g., by
abrading the cornea).
However, successes have been obtained
either by using natural or reconstructed tis-
sue equivalents that allow direct applica-
tion of test material to target cells [e.g.,
tissue equivalent assay (8) or the bovine
corneal opacity and permeability assay
(9)], or when use of the test system is
restricted to specific conditions such as
using the fluorescein leakage assay for very
mild surfactant-containing materials.
Strategies for Use. In vitro ocular
irritation assays can be most successfully
utilized by referring to Figure 1. There may
be sufficient information available in step 1
that allows a decision to be made, e.g.,
extreme pH coupled with high acid or alka-
line reserve may lead to a classification of
severe irritant. Ifa decision cannot be made
at this point, an appropriate ocular alterna-
tive method is conducted (step 3), ifone is
available. It is extremely important that only
appropriate methodologies are used, i.e.,
those that have been well evaluated (vali-
dated) for the specific type of test material
and degree of irritant response that could
be expected, and that have well-defined
prediction models.
The resulting information can then be
used in conjunction with information gath-
ered in step 1 to attempt to make a hazard
evaluation. It is possible that this infor-
mation is sufficient; indeed some safety deci-
sions are made at this stage today. However,
it may be that an appropriate in vitro test
does notyet exist for the type oftest material
being examined-or that the information
obtained from integrating the available data
is still not sufficient for a decision. Animal
tests (or human tests, if appropriate) may
then need to be conducted with the knowl-
edge that only a very limited study may be
necessary to supply the missing information
or to add to the confidence in the previous
data. For example, study of a single rabbit
may be sufficient to add the confidence
necessaryto label amaterial as nonirritating.
Barrers toProgress. Several barriers to
progress still exist. The major ones are
* Lackofhigh quality in vivodata (animals
or human) with which to calibrate and
subsequentlyvalidate in vitroassays and
their associated prediction models.
* Insufficient knowledge of the processes
involved in human eye injury. This
prevents improvement of current tests
so that they more accurately predict
human hazard.
* Robust in vitro models that can accom-
modate test materials with wide-ranging
physical characteristics and potential
toxicity.
* An adequate understanding ofrecovery
from eye injury, a process not examined
in any of the existing tests. Knowledge
of this phenomenon is very important
to risk assessment.
Recommendations
* Expand knowledge of toxic markers in
humans, especially those that are
predictive of permanent injury, and
develop in vitro tests in which the same
toxic markers can be observed.
* Continue research into characterizing
models where there is direct application
oftest material to the target cells.
* Conduct parallel in vitro testing
whenever an in vivo animal eye test is
conducted. Create a system that will
allow these paired data and the iden-
tity ofthe tested chemical to be easily
available to researchers in the area of
alternative models.
DermalToxicity
Dermal toxicity expresses itself either as
irritation or allergic contact sensitization.
Irritation (acute, primary, delayed, or trau-
matic) can occur rapidly or over years and
can exist as mild erytherma through vari-
ous degrees ofseverity resulting in disrup-
tion ofthe integrity ofskin, i.e., corrosion.
Allergic contact dermatitis is a cuta-
neous T-lymphocyte-mediated reaction to
exogenous chemicals.
Phototoxicity is a specialized case of
either irritancy or allergy but requires light
activation ofthe toxic chemical.
Numerous factors can modifythebiolog-
ical response oftheskin to exogenous chemi-
cals. Among the most important are age,
gender, race, and preexisting and previous
skin diseases.
Current Systems for Evaluation.
Historical animal and human data, QSAR,
and physical/chemical assays can provide
excellent data for initial evaluation and an
appropriate road map to identify necessary
studies. In some cases, if sufficient data
exists, the material can be evaluated with-
out further testing. In other cases it may be
possible to directly use these materials in
human testing.
A number ofin vitrobiological methods
are currently being used and/or evaluated
for their usefulness. These indude cell cul-
ture, reconstituted tissue equivalent (RTE),
and skin explants.
For irritation a number of biological
end points are used as a measure ofcellular
toxicity. Specific biochemical markers
interleukin-1 (ILl), arachidonic acid, and
the prostaglandins provide information on
this inflammatory process. Histopathology
and noninvasive techniques (e.g., trans-
epidermal water loss, CO2 transport) are
being evaluated mainly in RTE and in
skin explants.
A potential strategy for irritation can
be evaluated by using the general scheme
in Figure 2. Step 1 includes physical and
chemical properties, literature review,
QSAR, historical data, and physical/
chemical assays.
Once the data are integrated and evalu-
ated, then in vitromethods can be used (step
4). These could include cytotoxicity (e.g.,
Environmental Health Perspectives * Vol 106, Supplement 2 * April 1998 423CURREN ETAL.
MTT reduction end point), biochemical
measures, and histopathology. After further
integration and evaluation ofall data, it will
be possible, in many cases, to go directly to
human testing (step 9).
Corrosive testing, the extreme case of
irritation, may be evaluated completely in
step 1 as described above. In other cases
histopathology, biochemical, or Corrositex
testing may be required. Ifa known or sus-
pected corrosive material is being evaluated
for degree of severity, animal or human
testing is inappropriate.
For allergic contact dermatitis (ACD)
an understanding of the biological basis
will provide appropriate mechanistic tests
(10). Specific approaches are currently
under evaluation and one anticipates rapid
understanding and significant methodol-
ogy development. The biology of ACD
suggests that specific cytokines (and/or
their messenger RNA), adhesion mole-
cules, and histochemistry will provide
appropriate batteries oftests.
The biological systems most likely to be
used include keratinocyte cell cultures,
dendrite cell model (Langerhan cells
and/or blood monocytes), and RTE. The
results of ongoing QSAR studies are most
encouraging. In fact, one might anticipate
that QSAR and a single or limited battery
of in vitro tests will provide sufficient data
to identify and manage the risk of skin
contact allergens.
A potential strategy for ACD using the
general scheme in Figure 1 is step 1:
QSAR, historical data, and literature; step
4: cell or RTE with measurements of an
adhesion molecule, interleukin-8 (IL8),
and/orhistochemistry.
It is anticipated that in many cases
results from this approach will provide the
appropriate information to describe and
manage the riskofthese chemicals.
Next Steps and Current Needs. There
is a need to develop: a) more completely
defined biological systems necessary to
study dermal toxicity; b) better and more
accessible preparations of Langerhan cells
and/or model dendritic cell systems (e.g.,
blood monocytes); c) an expanded knowl-
edge base for adhesion molecules so that
relationships between exogenous chemicals
and changes in adhesion molecules are
understood; d) an understanding of the
relationships ofcytokines and other media-
tors of the inflammatory process with
exogenous irritant chemicals; and e) an
understanding of the interaction and time
relationships ofthe numerous cytokine and
adhesion molecules.
Acute OralToxicity
Data on acute oral toxicity are produced for
reasons that indude obtaining information
on the biological activity ofa chemical and
gaining insight into its mechanism of
action. Usuallylong-term studies beginwith
a dose-finding exercise under acute condi-
tions. Furthermore, the information on
acute systemic toxicity generated by the test
is used in hazard identification and risk
management for the production, handling,
transportation, and use of chemicals. The
LD50 value (precise or approximate) is cur-
rently the basis for toxicologic dassification
of chemicals and is thus required by the
regulatoryauthorities in differentsituations.
Status. Today all tests for acute
systemic toxicity rely on the use of labora-
tory animals. The original LD50 test (using
a large number of animals in each dose
group, two species, and both sexes) is out-
dated; there are no scientific or legal reasons
for performing the test. Nevertheless,
accepted new methods that fullfill both the
reduction and refinement criteria for
alternatives are based on animal studies.
Furthermore, the older, more animal inten-
sive alternatives are used more frequently
than the newer, more humane methods.
The general opinion is that nonanimal
methods, addressing the replacement crite-
rion, are not likely to come into use in
acute toxicitytesting in the near future.
The fact that correlations can be shown
between the blood concentration of a
chemical that is lethal to man and the con-
centration that kills a defined fraction of
the population ofcells in culture indicates
that in vitro alternatives are possible to
develop. These postulated nonanimal
methods will inevitably have to be more
complicated than just simple cytotoxicity
measurements. It is already clear that the
prediction ofhuman toxicity by cytotoxic-
itymeasurements is greatlyimproved bythe
introduction of biokinetic information in
the prediction model. Such information
can be obtained from in vivo or in vitro
studies orphysiology-based computor mod-
els of kinetics. However, if one considers
the possibility of replacing some isolated
aspects ofacute systemic testing, e.g., dose-
finding or quantitative determinations
(LD50 value finding), cytotoxicity determi-
nations represent at leastpartial alternatives.
There is obviously a role for in vitro assays
in acute toxicity testing as outlined in
Figure 1.
Strategiesfor Use.Acute systemic toxi-
city should be seen in the context of the
stepwise procedure presented in Figure 2.
The collection (step 1) and integration
(step 2) of information on physical and
chemical properties ofa compound, litera-
ture reviews, and an analysis of the struc-
ture-activity relationships, when possible,
are always desirable before any testing of
toxicity begins. However, this information
will not be sufficient to allow a definite
judgment on the systemic toxicity of the
compound (step 3); biological tests will
still be necessary. It is therefore recom-
mended that acute systemic toxicity testing
(step 4) begin with the determination of
general cytotoxicity in an in vitro system.
Data on gastrointestinal uptake, on the
penetration ofthe blood-brain barrier, and
on biotransformation may be obtained
using in vitro models. Furthermore, this
information can be reinforced and supple-
mented (distribution and elimination data)
by the use of computer-based biokinetic
modeling. When integrated (step 5) with
steps 1 and 2 the in vitro results may pro-
vide sufficient information for an evalua-
tion of hazard (step 6). If not, the animal
studies (step 8) can be performed with a
wealth of background information and
thus a minimum use oflaboratory animals.
When the hazard characterization is com-
pleted, it may be appropriate to perform
human studies of acute systemic toxicity
(step 7) as in the case ofdrug development,
where confirmation of the lack of toxicity
in the therapeutic dose range is required.
Barriers to Progress. To successfully
perform acute systemic toxicity testing
according to the strategyoutlined above, the
followingproblems have to be addressed:
* There is insufficient information on
structure-activity relationships with
respect to acute systemic toxicity. This
may be explained by the fact that a
large number of mechanisms partici-
pate in the expression of this type of
toxicity (see organ toxicity section).
Substantial additional investigation of
the cause ofchemicallyinducedlethality
is needed.
* The in vitro models used to determine
gastrointestinal uptake, blood-brain
barrier passage, and biotransformation
are currently and frequently used in
pharmacology and toxicity studies.
However, those methods have not been
formally validated. This is needed to
identify the most reliable ones.
* Projects are ongoing to establish pro-
cedures for the integration of in vitro
data into hazard characterization.
However, more efforts must be directed
to promote cooperative programs in the
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development of alternatives to acute
toxicity testing.
* In spite of a number of in vivo alter-
natives for oral acute toxicity testing,
the most frequently used are the more
traditional, animal-intense methods.
Therefore, active measures must be
taken to phase out older methods and
to promote more humane alternatives.
Conclusions Regarding Acute
Toxicity Testing in General
* A great deal ofeffort has been directed
toward development and validation of
alternative methods for acute toxicity
testing.
* Validation and acceptance have occurred
on manydifferent levels, e.g., within sin-
gle laboratories and within individual
companies. These methods are routinely
used in the riskassessment process.
* Some alternative tests for reduction and
refinement have been validated and
accepted by international authorities
(OECD). Examples of new methods
include the fixed-dose procedure and
limit test for acute oral toxicity testing,
and the refinement ofguidelines for eye
irritation testing.
* Some alternative methods have been val-
idated for limited use in the risk assess-
ment process. Some of these methods
are used routinely.
* No single battery ofalternative assays has
been validated as a complete replacement
for an acute toxicity test.
* This substantial progress in the success-
ful use of QSAR, cell and molecular
biology, computer modeling, and statis-
tics leads us to conclude that use of
nonanimal alternative methods is a strat-
egy that improves acute toxicity testing
and the safetyevaluation ofchemicals.
* Recently completed validation studies
have led to substantial refinements in
the validation process. These improve-
ments will allow faster, more efficient,
and objective assessment of alternative
methods in the future.
Recommendations
* Continued support ofthe development
and validation ofalternative methods is
essential and is expected to lead to
continued improvement in the safety
evaluation ofchemicals.
* Research should be directed toward a
better understanding of the relevant
biology (especially human) of the toxic
events and mechanisms.
* Development of better methods for
synthesizing the information obtained
from the battery of alternative tests to
improve the interpretation of the inte-
grated results is needed.
* Users of alternative methods should
adopt the general scheme for toxicity
testing (Figure 1).
* Validated and accepted alternative meth-
ods should be immediately utilized.
Implementation of methods providing
equivalent information should be priori-
tized according to the degree that they
use feweranimals or causeless stress.
* Given the expected rapid progress in the
development of new alternative meth-
ods, it is recommended that scientists,
regulators, potential users, and policy-
makers establish and use continuing
education and information distribution
programs to staycurrent with progress.
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